Evidence map›Paper›PMID 35005470›Full record

ArticleIJU case reports2022

First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with

Minami Omura, Takeo Kosaka, Eriko Aimono, Kohei Nakamura, Hiroshi Hongo, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IJU case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Minami OmuraDepartment of Urology Keio University School of Medicine Tokyo Japan.
Takeo KosakaDepartment of Urology Keio University School of Medicine Tokyo Japan.ORCID https://orcid.org/0000-0002-4371-4594
Eriko AimonoGenomics Unit Keio Cancer Center Keio University School of Medicine Tokyo Japan.
Kohei NakamuraGenomics Unit Keio Cancer Center Keio University School of Medicine Tokyo Japan.
Hiroshi HongoDepartment of Urology Keio University School of Medicine Tokyo Japan.
Shuji MikamiDivision of Diagnostic Pathology Keio University Hospital Tokyo Japan.
Hiroshi NishiharaGenomics Unit Keio Cancer Center Keio University School of Medicine Tokyo Japan.
Mototsugu OyaDepartment of Urology Keio University School of Medicine Tokyo Japan.
Keio University · JPKeio University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDeoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. CASE PRESENTATION: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting

conclusionThrough a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

Indexed as

BRCA2 mutationcase reportDNA repairprognosistreatment outcome

Identifiers

PMID35005470
PMCPMC8720712
OpenAlexW3209424192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.